Hosted on MSN

Is Novo Nordisk Stock a Buy Now?

Novo Nordisk has recently encountered headwinds in its core therapeutic area. The company has implemented changes that could pay off in the long run. Novo Nordisk's shares look reasonably valued. 10 ...
Morningstar

Novo Nordisk: Restructuring Sets the Stage for Long-Term Investment in Diabetes and Obesity

Novo Nordisk announced a restructuring plan to be implemented during the third quarter. Management lowered constant currency operating profit growth guidance for 2025 ...
Reuters

Wegovy maker Novo hit with investor class action over revenue forecast cut

Aug 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab, maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish pharmaceutical giant misled them with ...

Eli Lilly Vs Novo Nordisk: One To Walk Away From And One To Run Away From

Discover how potential U.S. price cuts on obesity drugs could impact LLY and NVO revenues, stock sentiment, and valuation ...
The Motley Fool

Should You Buy Novo Nordisk Right Now?

Novo Nordisk is drawing divided views from Wall Street analysts. Some may be disappointed by the loss of market share to Eli Lilly. Three events could turn sentiment positive in the coming months. The ...

Novo Nordisk: Decade-Low Valuation Meets A Billion-Patient Market

Sure, Eli Lilly’s Tirzepatide-based drugs have caught up significantly to Novo Nordisk’s semaglutide-based ones. As a result, ...
Boston Herald

Novo Nordisk, maker of obesity drug Wegovy, to cut 9,000 jobs to sharpen focus, meet competition

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk, maker of weight-loss drug Wegovy, said Wednesday it would cut 9,000 jobs, 5,000 of them in Denmark, in order to strengthen the ...